Urovant Sciences Ltd. (UROV)


Urovant Sciences Ltd. (UROV)

$7.99 USD

0.00 (0.00%)

Updated Jun 25 8:00pm

Add UROV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 207 in Medical - Pharmaceuticals

See all “A” rated Strong Buy stocks

UROV Daily Price Range
UROV 52-Week Price Range

UROV News Stream

Event/Time News Detail Start End Change
Loading, please wait...
View All UROV News

Urovant Sciences Ltd. (UROV) Company Bio


Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

UROV Stock Chart More Charts


UROV Price/Volume Stats

Current price $7.99
Prev. close $7.99
Day low $7.86
Day high $8.20
50-day MA $7.93
200-day MA $0.00
52-week high $14.49
52-week low $4.05
Volume 88,400
Avg. volume 62,388
Dividend yield N/A
Market Cap 242.34M

UROV Social Stream


Loading social stream, please wait...

View Full UROV Social Stream

UROV Returns

1-mo 4.86%
3-mo -20.10%
6-mo 27.64%
1-year N/A
3-year N/A
5-year N/A
YTD 21.24%
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A
Page generated in 0.3342 seconds.